Annual report pursuant to Section 13 and 15(d)

Stockholders' Deficit (Details Narrative)

Stockholders' Deficit (Details Narrative) - USD ($)							12 Months Ended
Stockholders' Deficit (Details Narrative) - USD ($)	Jun. 10, 2020	Jun. 09, 2020	Dec. 23, 2019	Nov. 05, 2018	Jun. 28, 2018	Sep. 27, 2017	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	May 31, 2020	May 07, 2020	Sep. 18, 2018	May 09, 2018
Common stock shares authorized							10,000,000,000	10,000,000,000				10,000,000,000
Common stock par value							$ 0.0001	$ 0.0001				$ 0.0001
Preferred stock shares authorized							5,000,000	5,000,000				5,000,000
Preferred stock par value							$ 0.01	$ 0.01				$ 0.01
Number of common stock issued, value								$ 4,619,150
Number of common stock issued on conversion								$ 8,128,044
Common stock shares issued							9,648,936,775	128,567,273
Common stock shares outstanding							9,648,936,775	128,567,273
Recognized stock stock-based compensation							$ (51,899)	$ 285,992
Reverse stock split, description				1-for-500 reverse stock split
2007 Equity Plan [Member]
Stock option expense							$ 51,900	100,000
Weighted average period							6 years 3 months 29 days
Intrinsic value of options exercisable							$ 0	$ 0
Subsequent Event [Member]
Common stock shares outstanding										9,898,936,775
Number of shares converted	5,000,000
Reverse stock split, description		The Company's shareholders approved an amendment to the Company's Certificate of Incorporation, as amended, to effect a reverse stock split of all of the outstanding shares of the Company's common stock, at a specific ratio from 1-for-100 to 1-for-10,000, and to grant authorization to its Board of Directors to determine, in its discretion, the specific ratio and timing of the reverse split at any time on or before December 31, 2020, subject to the Board of Directors' discretion to abandon such amendment.
March 2017 Debentures [Member]
Number of warrants exercisable into common stock							564,800,000
Warrants exercise price							$ 0.000085
September 2017 Debentures [Member]
Number of warrants exercisable into common stock							69,355
Warrants exercise price							$ 390.0
Employees and Directors [Member] \| Restricted Stock [Member]
Number of restricted stock issued								142,667
Recognized stock stock-based compensation								$ 477,933	$ 189,209
Stock issued price per share								$ 3.35
Increase In Authorized Shares [Member]
Common stock shares authorized													3,000,000,000
Series A Warrants [Member] \| March 2017 Debentures [Member]
Number of warrants exercisable into common stock							211,300,000
Warrants exercisable term							5 years
Series A Warrants [Member] \| September 2017 Debentures [Member]
Number of warrants exercisable into common stock							23,118
Warrants exercisable term							5 years
Series B Warrants [Member] \| March 2017 Debentures [Member]
Number of warrants exercisable into common stock							135,200,000
Warrants exercisable term							18 months
Series B Warrants [Member] \| September 2017 Debentures [Member]
Number of warrants exercisable into common stock							23,119
Warrants exercisable term							5 years
Series C Warrants [Member] \| March 2017 Debentures [Member]
Number of warrants exercisable into common stock							218,300,000
Warrants exercisable term							5 years
Series C Warrants [Member] \| September 2017 Debentures [Member]
Number of warrants exercisable into common stock							23,118
Warrants exercisable term							5 years
Common Stock [Member]
Conversion of stock into shares					40,000			4,221,601
Number of common stock issued							119,615,384	17,788,579
Number of common stock issued, value							$ 11,962	$ 1,779
Number of common stock issued on conversion								$ 422
Number of shares converted								106,335,991
Cashless exercise warrants							119,615,384
Number of restricted stock issued								142,667
Common Stock [Member] \| Subsequent Event [Member]
Common stock shares issued											53,368
Common Stock [Member] \| Issued Upon Conversion [Member]
Number of common stock issued							9,400,754,118
Warrants [Member]
Number of warrants issued as anti-dilution provision							582,200,000,000	53,200,000
Series H Preferred Stock [Member]
Preferred stock shares authorized							14,202	14,202
Preferred stock par value							$ 0.01	$ 0.01
Preferred stock shares outstanding							10	60
Preferred stock, stated value							$ 1,000
Weighted average common stock price percentage							85.00%
Conversion of stock into shares					50
Series F Convertible Preferred Stock [Member]
Preferred stock shares outstanding							1,750,000
Series F Convertible Preferred Stock [Member] \| Genomas, Inc [Member]
Conversion of stock into shares						120
Number of common stock issued						1,750,000
Number of common stock issued, value						$ 174,097
Number of common stock issued on conversion						$ 14,625
Preferred stock price per share for unpaid dividend						$ 1.95
Series J Convertible Preferred Stock [Member]
Preferred stock shares outstanding							250,000
Series G Preferred Stock [Member]
Preferred stock shares authorized							14,000	14,000
Preferred stock par value							$ 0.01	$ 0.01
Preferred stock shares outstanding							0	215
Preferred stock, stated value							$ 1,000
Weighted average common stock price percentage							85.00%
Preferred stock redeemed shares							100
Conversion of stock into shares
Number of common stock issued
Number of common stock issued, value
Number of common stock issued on conversion
Series H Preferred Stock [Member]
Preferred stock, stated value							$ 1,000
Conversion of stock into shares								(50)
Number of common stock issued
Number of common stock issued, value
Number of common stock issued on conversion
Series K Preferred Stock [Member]
Preferred stock shares authorized							250,000	250,000
Preferred stock par value							$ 0.01	$ 0.01
Preferred stock shares outstanding							250,000	0
Conversion of stock into shares
Number of common stock issued
Number of common stock issued, value
Number of common stock issued on conversion
Series K Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value			$ 250,000
Cumulative dividends percentage			8.00%
Series J Preferred Stock [Member]
Preferred stock shares authorized							250,000	250,000
Preferred stock par value							$ 0.01	$ 0.01
Preferred stock shares outstanding							0	250,000
Conversion of stock into shares
Number of common stock issued								250,000
Number of common stock issued, value								$ 2,500
Number of common stock issued on conversion
Series J Preferred Stock [Member] \| Exchange Agreement [Member] \| Alcimede LLC [Member]
Number of shares issued upon conversion, value			$ 250,000
Series I-2 Preferred Stock [Member]
Number of common stock issued on conversion								$ 1,500,000
Number of shares issued upon conversion, value							$ 1,500,000
Number of shares converted							1,078.63	1,286.141